THE PRO-INFLAMMATORY ROLE OF MICRORNA-29b IN DIABETIC NEPHROPATHY
Objectives: The objective of the study was to investigate the expression pattern of microRNA-29b (miRNA-29b) in patients with diabetic nephropathy (DN) compared to Type 2 diabetes mellitus (T2DM) and healthy subjects.
Methods: Blood samples were obtained from 30 patients with DN, 30 patients with T2DM and 30 healthy subjects as controls. Serum reactive oxygen species (ROS) and interleukine-10 (IL-10) level were measured by enzyme-linked immunosorbent assay, and quantitative polymerase chain reaction was employed to screen the expression of serum miRNA-29b and anti-apoptotic B-cell lymphoma 2 (Bcl-2).
Results: The results showed a significant increase in ROS levels (p<0.05) in DN group compared with T2DM and control groups. IL-10 levels were significantly increased compared to other groups (p<0.05). The gene expression of miRNA-29b was significantly increased with downregulation of Bcl-2 (p<0.05) in DN compared to T2DM and control groups (p<0.05).
Conclusions: The study suggested that miRNA-29b expression is involved in the pathogenesis of DN. Hyperglycemia induced oxidative stress-mediated apoptosis, and an increase in expression of pro-inflammatory miRNA-29b exerts anti-protective effect by upregulating target genes related to inflammation and apoptosis, taken together, the results identify the regulatory role of miRNA-29b in DN.
2. Tervaert TW, Mooyaart AL, Amann K, Cohen AH, Cook HT, Drachenberg CB, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 2010;21:556-63.
3. Mohammad JI, Chigrupati S, Othman AS, Iqbal MZ. Diabetes nephropathy an obvious complication in long term Type 1 diabetes mellitus: A case study. Asian J Pharm Clin Res 2017;10:4-7.
4. Haghighatpanah GT, Jha A, Mallayasamy S. Study on prescribing pattern of anti-diabetic drugs among Type 2 diabetes patients with complication in South Indian teaching hospital. Asian J Pharm Clin Res 2016;9 Suppl 1:194-7.
5. Mosser DM, Zhang X. Interleukin-10: New perspectives on an old cytokine. Immunol Rev 2008;226:205-18.
6. Skommer J, Wlodkowic D, Deptala A. Larger than life: Mitochondria and the bcl-2 family. Leuk Res 2007;31:277-86.
7. Verzola D, Bertolotto MB, Villaggio B, Ottonello L, Dallegri F, Frumento G, et al. Taurine prevents apoptosis induced by high ambient glucose in human tubule renal cells. J Investig Med 2002;50:443-51.
8. Hotchkiss RS, Strasser A, McDunn JE, Swanson PE. Cell death.N Engl J Med 2009;361:1570-83.
9. Cho MH. Renal fibrosis. Korean J Pediatr 2010;53:735-40.
10. Kozomara A, Griffiths-Jones S. MiRBase: Integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 2011;39:D152-7.
11. Samuel VT, Shulman GI. Mechanisms for insulin resistance: Common threads and missing links. Cell 2012;148:852-71.
12. Kriegel AJ, Liu Y, Fang Y, Ding X, Liang M. The miR-29 family: Genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol Genomics 2012;44:237-44.
13. ?lusarz A, Pulakat L. The two faces of miR-29. J Cardiovasc Med (Hagerstown) 2015;16:480-90.
14. Long J, Wang Y, Wang W, Chang BH, Danesh FR. MicroRNA-29c is a signature microRNA under high glucose conditions that targets sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy. J Biol Chem 2011;286:11837-48.
15. Kaneto H, Katakami N, Matsuhisa M, Matsuoka TA. Role of reactive oxygen species in the progression of Type 2 diabetes and atherosclerosis. Mediators Inflamm 2010;2010:453892.
16. Miranda-Díaz AG, Pazarín-Villaseñor L, Yanowsky-Escatell FG, Andrade-Sierra J. Oxidative stress in diabetic nephropathy with early chronic kidney disease. J Diabetes Res 2016;2016:7047238.
17. Schoonmaker GC, Fallet RW, Carmines PK. Superoxide anion curbs nitric oxide modulation of afferent arteriolar ANG II responsiveness in diabetes mellitus. Am J Physiol Renal Physiol 2000;278:F302-9.
18. Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 2005;54:1615-25.
19. Rao C, Rao S, Prasad KH, Vidya B. Catalase and malondialdehyde levels: Possible markers for Type 2 diabetes mellitus. Euro J Biomed Pharm Sci 2017;4:232-7.
20. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011;11:98-107.
21. My?liwska J, Zorena K, Semetkowska-Jurkiewicz E, Racho? D, Suchanek H, My?liwski A, et al. High levels of circulating interleukin-10 in diabetic nephropathy patients. Eur Cytokine Netw 2005;16:117-22.
22. Bakheet MS. Interleukin 10 gene polymorphisms and susceptibility to nephropathy in Egyptian diabetic patients. Int J Biochem Res Rev 2017;17:1-11.
23. Gill PS, Wilcox CS. NADPH oxidases in the kidney. Antioxid Redox Signal 2006;8:1597-607.
24. Sugiyama H, Kashihara N, Makino H, Yamasaki Y, Ota A. Apoptosis in glomerular sclerosis. Kidney Int 1996;49:103-11.
25. Pullen TJ, da Silva Xavier G, Kelsey G, Rutter GA. MiR-29a and miR-29b contribute to pancreatic beta-cell-specific silencing of monocarboxylate transporter 1 (Mct1). Mol Cell Biol 2011;31:3182-94.
26. Vikman J, Ma X, Hockerman GH, Rorsman P, Eliasson L. Antibody inhibition of synaptosomal protein of 25 kDa (SNAP-25) and syntaxin 1 reduces rapid exocytosis in insulin-secreting cells. J Mol Endocrinol 2006;36:503-15.
27. Shin ES, Sorenson CM, Sheibani N. Diabetes and retinal vascular dysfunction. J Ophthalmic Vis Res 2014;9:362-73.
28. Peng H, Zhong M, Zhao W, Wang C, Zhang J, Liu X, et al. Urinary miR-29 correlates with albuminuria and carotid intima-media thickness in Type 2 diabetes patients. PLoS One 2013;8:e82607.
29. Zhu HQ, li Q, Dong LY, Zhou Q, Wang H, Wang Y, et al. MicroRNA-29b promotes high-fat diet-stimulated endothelial permeability and apoptosis in apoE knock-out mice by down-regulating MT1 expression. Int J Cardiol 2014;176:764-70.
30. Mott JL, Kobayashi S, Bronk SF, Gores GJ. Mir-29 regulates mcl-1 protein expression and apoptosis. Oncogene 2007;26:6133-40.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.